Compare ESP & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | ALXO |
|---|---|---|
| Founded | 1928 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 205.9M |
| IPO Year | 1995 | 2020 |
| Metric | ESP | ALXO |
|---|---|---|
| Price | $63.69 | $1.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $64.00 | $3.50 |
| AVG Volume (30 Days) | 20.3K | ★ 618.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $22.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.00 | $1.02 |
| 52 Week High | $74.77 | $2.66 |
| Indicator | ESP | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 42.12 |
| Support Level | $61.50 | $1.56 |
| Resistance Level | $67.31 | $2.17 |
| Average True Range (ATR) | 1.48 | 0.09 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 38.58 | 19.64 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.